Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lacunar-Brain Infarction Cerebral Hyperactivity And Atorvastatin Trial. A Placebo-Controlled Trial Of High-Dose Atorvastatin In Patients With Cerebral Small Vessel Disease.
Brief Summary: The main purpose of this study is to evaluate the efficacy of atorvastatin treatment during 3 months (80mg/day) on cerebral vasoreactivity (CVR) in lacunar patients.


Options:
A: Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A
C: Arm Label: 30 milligram (mg) LY2484595 monotherapy; Type: EXPERIMENTAL; Interventions: Drug: LY2484595, Drug: Placebo for Statins | Arm Label: 100 mg LY2484595 monotherapy; Type: EXPERIMENTAL; Interventions: Drug: LY2484595, Drug: Placebo for Statins | Arm Label: 500 mg LY2484595 monotherapy; Type: EXPERIMENTAL; Interventions: Drug: LY2484595, Drug: Placebo for Statins | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for LY2484595, Drug: Placebo for Statins | Arm Label: 20 mg Atorvastatin monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo for LY2484595 | Arm Label: 100 mg LY2484595 + 20 mg Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: LY2484595, Drug: Atorvastatin | Arm Label: 40 mg Simvastatin monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo for LY2484595 | Arm Label: 100 mg LY2484595 + 40 mg Simvastatin; Type: EXPERIMENTAL; Interventions: Drug: LY2484595, Drug: Simvastatin | Arm Label: 10 mg Rosuvastatin monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: Placebo for LY2484595 | Arm Label: 100 mg LY2484595 + 10 mg Rosuvastatin; Type: EXPERIMENTAL; Interventions: Drug: LY2484595, Drug: Rosuvastatin | Intervention Type: DRUG; Name: LY2484595; Assigned to Arm(s): 100 mg LY2484595 + 10 mg Rosuvastatin, 100 mg LY2484595 + 20 mg Atorvastatin, 100 mg LY2484595 + 40 mg Simvastatin, 100 mg LY2484595 monotherapy, 30 milligram (mg) LY2484595 monotherapy, 500 mg LY2484595 monotherapy | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 100 mg LY2484595 + 20 mg Atorvastatin, 20 mg Atorvastatin monotherapy | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): 100 mg LY2484595 + 40 mg Simvastatin, 40 mg Simvastatin monotherapy | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 10 mg Rosuvastatin monotherapy, 100 mg LY2484595 + 10 mg Rosuvastatin | Intervention Type: DRUG; Name: Placebo for LY2484595; Assigned to Arm(s): 10 mg Rosuvastatin monotherapy, 20 mg Atorvastatin monotherapy, 40 mg Simvastatin monotherapy, Placebo | Intervention Type: DRUG; Name: Placebo for Statins; Assigned to Arm(s): 100 mg LY2484595 monotherapy, 30 milligram (mg) LY2484595 monotherapy, 500 mg LY2484595 monotherapy, Placebo
D: Arm Label: Group 1: 0 g/day; Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Arm Label: Group 2: 1.25 g/day; Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Arm Label: Group 3: 2.5 g/day; Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Arm Label: Group 4: 5 g/day; Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Arm Label: Group 5: 10* g/day; Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Arm Label: Group 6: Placebo/Placebo (PBO/PBO); Type: EXPERIMENTAL; Interventions: Drug: Testosterone, Drug: Goserelin acetate | Intervention Type: DRUG; Name: Testosterone; Assigned to Arm(s): Group 1: 0 g/day, Group 2: 1.25 g/day, Group 3: 2.5 g/day, Group 4: 5 g/day, Group 5: 10* g/day, Group 6: Placebo/Placebo (PBO/PBO) | Intervention Type: DRUG; Name: Goserelin acetate; Assigned to Arm(s): Group 1: 0 g/day, Group 2: 1.25 g/day, Group 3: 2.5 g/day, Group 4: 5 g/day, Group 5: 10* g/day, Group 6: Placebo/Placebo (PBO/PBO)

Answer: A